|
|
Article: Sicel Technologies, Inc. Receives U.S. Food & Drug Administration Clearance for DVS[R]-HFT, a Next-Generation Wireless Sensor to Measure Actual Radiation Dose at Breast and Prostate Tumor Site.
- Article from:
- Cancer Weekly
- Article date:
- March 24, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sicel Technologies, Inc. announced it has received clearance from the U.S. Food and Drug Administration to begin marketing DVS[R]-HFT, the next-generation of the companyEs original DVS (Dose Verification System) wireless implantable dosimeter that remains the only device to measure actual radiation dose at the tumor site for use in treating breast and prostate cancer patients undergoing external beam radiation therapy (see also Sicel Technologies, Inc.).
The medical device expands Sicel TechnologiesE portfolio, because the DVS-HFT dosimeter is specifically calibrated for use with radiation therapy protocols that give patients higher single doses of radiation over ...